Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 1;15(2):253–264. doi: 10.7150/ijbs.27420

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Ivyspring International Publisher

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Adiponectin inhibited the proliferation of human pancreatic cancer cells through its receptors in vitro.A, BxPC-3 cells were left untreated or were treated with AdipoQ at the indicated concentrations for 72 h, and then the cell proliferation was determined via a CCK-8 assay. The results are expressed as the absorbance at 450 nm. Note that adiponectin inhibited the proliferation of BxPC-3 cells in a dose-dependent manner. B, Cell proliferation assay was also performed on BxPC-3 and CFPAC-1 cells viaCCK-8 assay after the cells were treated with AdipoQ(40 μg/ml) in the presence of 10% FBS for the indicated time durations. Untreated cells were used as controls. C and D, BxPC-3 and CFPAC-1 cells were infected with a recombinant lentivirus carrying the human adiponectin gene (adiponectin-overexpressing cells: BxPC-3-AdipoQ and CFPAC-1-AdipoQ) or an empty virus (control cells: BxPC-3-VC and CFPAC-1-VC). C,A western blot analysis of the expression of adiponectin in BxPC-3-AdipoQ and BxPC-3-VC cells. D, The cell proliferation of the infected BxPC-3 and CFPAC-1 cells was determined via CCK-8 assay in the presence of 10% FBS. E, Cell proliferation assay was performed on BxPC-3 and CFPAC-1 cells via CCK-8 assay after the cells were treated with AdipoQ (40 μg/ml) in the presence of 2% FBS for the indicated time durations. Untreated cells were used as controls. F, The cell proliferation of the infected BxPC-3 and CFPAC-1 cells was determined via CCK-8 assay in the presence of 2% FBS. G,The protein expression of adiponectin receptors AdipoR1 and AdipoR2 in BxPC-3 and CFPAC-1 cells was analyzed by western blot. H, A western blot analysis of the expression of adiponectin receptors in the RNAi-mediated AdipoR-knockdown cells (BxPC-3-siAdipoR1/2) and control cells (BxPC-3-scRNA).J, Both BxPC-3-siAdipoR1/2 and BxPC-3-scRNA cells were left untreated or were treated with adiponectin (40 μg/ml)for 72 h in the presence of 10% FBS (Left) or 2% FBS (Right), and then the cell proliferation was determined via a CCK-8 assay. AdipoQ, adiponectin. Data are expressed as the mean ± SEM of 3-4 independent experiments. *P< 0.05; **P< 0.01.